{
    "clinical_study": {
        "@rank": "134517", 
        "arm_group": {
            "arm_group_label": "second trimester abortion , feticide", 
            "arm_group_type": "Experimental", 
            "description": "all patients admitting to second trimester abortion above 22 weeks will be injected intra-amniotic DIGOXIN for feticide ."
        }, 
        "brief_summary": {
            "textblock": "In second trimester abortion above 22 weeks the investigators usually inject intra-cardiac\n      Kcl for feticide. Digoxin intra-amniotic injection has been described in the literature in\n      doses of 1-1.5 mg. with a success rate of about 80%, and up to 24 weeks. Our aim in this\n      study is to investigate the safety and success rate of 1.5-2 mg. digoxin, intra-amniotic up\n      to 30 weeks pregnancy ."
        }, 
        "brief_title": "Intra Amniotic Injection of DIGOXIN for Feticide in Second Trimester Termination of Pregnancy", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Arrhythmia", 
            "ECG Changes", 
            "Hypotension"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Arrhythmias, Cardiac", 
                "Hypotension"
            ]
        }, 
        "detailed_description": {
            "textblock": "-  The digoxin will be injected intra-amniotic with U.S guided, trying to avoid any\n           placental passage or intravascular injection /\n\n        -  Any patient will have prior to the procedure a full examination including E.C.G and\n           cardiac clearance."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  healthy women with no medical, cardiac, hypertension, liver or renal problems  -\n             pregnant in their 20-30 week gestation,\n\n          -  that need to have abortion due to fetal anomalies or any other reason\n\n          -  need to have feticide prior to the procedure\n\n        Exclusion Criteria:\n\n          -  any patient with medical problem that may be a contra-indication to Digoxin\n\n          -  cardiac problems,\n\n          -  prior cardiac surgery,\n\n          -  liver or kidney disease,\n\n          -  hyper tension etc."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 16, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01951079", 
            "org_study_id": "MMC130077-12CTIL"
        }, 
        "intervention": {
            "arm_group_label": "second trimester abortion , feticide", 
            "intervention_name": "Intra-amniotic injection of DIGOXIN", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Digoxin"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Digoxin", 
            "Intra-amniotic injection", 
            "feticide", 
            "second trimester abortion"
        ], 
        "lastchanged_date": "September 23, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Kefar-saba", 
                        "country": "Israel"
                    }, 
                    "name": "Sapir medical center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kefar-saba", 
                        "country": "Israel"
                    }, 
                    "name": "Dr. Zvi Klein"
                }
            }
        ], 
        "location_countries": {
            "country": "Israel"
        }, 
        "number_of_arms": "1", 
        "official_title": "The Safety and Outcome of Intra-amniotic DIGOXIN Injection for Feticide Prior to Second Trimester Abortion", 
        "overall_contact": {
            "email": "kleinz@clalit.org.il", 
            "last_name": "Zvi Klein, M.D", 
            "phone": "972-9-7472544"
        }, 
        "overall_contact_backup": {
            "last_name": "Regina agizim, M.D.", 
            "phone": "972-9-7472561"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Israel : Clalit Health Services", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To measure the Success rate of intra-amniotic Digoxin injection for feticide prior to second trimester abortion", 
            "measure": "Efficiency of intra-amniotic Digoxin injection for second trimester feticide", 
            "safety_issue": "Yes", 
            "time_frame": "a year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01951079"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Meir Medical Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Meir Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}